CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tiziana Life Sciences Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tiziana Life Sciences Ltd
3Rd Floor, 11-12 St. James's Square
Phone: +44 2074952379p:+44 2074952379 LONDON, SW1Y 4LB  United Kingdom
Business Summary
Tiziana Life Sciences Ltd is a United-Kingdom based clinical stage biotechnology company. The Company is focused on the discovery and development of novel molecules and related diagnostics to treat unmet medical needs in oncology and immunology. Its lead product candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501), and Milciclib TZLS-201. Foralumab (TZLS-401) is a fully human engineered anti-human cluster of differentiation 3 (CD3) monoclonal antibody (mAb). Foralumab is developed for the treatment of neurodegenerative diseases such as progressive Multiple Sclerosis (MS), and Crohn’s disease. The Anti IL-6R mAb (TZLS-501) is a fully human engineered mAb targeting the interleukin-6 receptor (IL-6R). Anti-IL-6R antibody can be used in combination with Foralumab or other anti-inflammatory and anti-infective agents as therapy for COVID-19 and oncology indications. The Company has developed Milciclib TZLS-201 for the treatment of hepatocellular carcinoma (HCC).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202212/31/2022Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Gabriele M.Cerrone 50 4/24/2014 4/24/2014
Chief Executive Officer, Chief Scientific Officer, Executive Director KunwarShailubhai 65 6/12/2017 1/23/2015
Finance Director KeerenShah
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
AccuStem Sciences Inc 5 Penn Plaza, 19Th Floor, #1954 NEW YORK NY United States

Business Names
Business Name
AccuStem Sciences Ltd
Longevia Genomics S.r.l.
LonGevia Genomics Srl
10 additional Business Names available in full report.

General Information
Number of Employees: 9 (As of 12/31/2022)
Outstanding Shares: 102,272,614 (As of 12/31/2022)
Shareholders: 1,196
Stock Exchange: LON


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024